Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing and trading of 141,953,489 H shares converted from previously unlisted domestic shares under its H Share Full Circulation plan. The conversion involves 28 participating shareholders, including multiple institutional and partnership investors, and will expand the company’s free float in the Hong Kong market, potentially improving liquidity of its shares and broadening its international investor base, which may strengthen its capital markets profile and support future financing flexibility.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology and pharmaceutical company based in mainland China and listed in Hong Kong, focusing on the development and commercialization of innovative vaccines and related biopharmaceutical products for both domestic and international markets.
Average Trading Volume: 102,858
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.33B
For a thorough assessment of 2179 stock, go to TipRanks’ Stock Analysis page.